GLP-1 Receptor Agonist Market Size, Share & Trends Analysis Report By Type (Victoza, Ozempic, Saxenda, Trulicity, Bydureon), By Region (North America, Europe, APAC, Latin America, MEA), And Segment Forecasts, 2020 - 2027
GLP-1 Receptor Agonist Market Growth & Trends
The global GLP-1 receptor agonist market size is expected to reach USD 18.2 billion by 2027, expanding at a CAGR of 6.1%, according to a new report by Grand View Research, Inc. The strong product pipeline and formulation advancements are driving the market. In addition, novel innovative products are booming the market. In September 2019, Rybelsus, the first and only oral GLP-1 analog was approved by the U.S.FDA for improving the glycemic control in type-2 diabetes patients. It is a semaglutide-based product developed by Novo Nordisk, which is currently under review by European Medicines Agency (EMA) and Pharmaceuticals and Medical Devices Agency (PMDA). After receiving the approval, the market may witness significant growth over the forecast period.
Furthermore, pharmaceutical companies are focusing on research collaborations for developing new GLP-1 products. For instance, in September 2018, Eli Lilly and Company entered into a license agreement with Chugai Pharmaceutical Co., Ltd for OWL833. OWL833 is Chugai’s proprietary oral GLP-1 agonist candidate and as per the agreement Eli Lilly will obtain global commercialization and development rights.
The companies are currently aiming on geographical expansion for increasing the sales output. Novo Nordisk is expanding its business by investing in the manufacturing unit located in North Carolina. The company holds around 50.0% of the market share of GLP-1 receptor agonists and is expected to dominate the market over the forecast period. Furthermore, in July 2018, Sanofi invested about USD 74.1 million in China for establishing an R&D hub to enhance its global reach.
The companies are also focusing on getting approval for other indications like obesity and major adverse cardiovascular events by authorities like the U.S.FDA, EMEA, and others for the existing products to increase their life cycle. For instance, in January 2020, Novo Nordisk received the U.S. FDA approval for Ozempic for Major Adverse Cardiovascular Events (MACE) in type 2 diabetes patients.
GLP-1 Receptor Agonist Market Report Highlights
The global GLP-1 receptor agonist market size is expected to reach USD 18.2 billion by 2027, expanding at a CAGR of 6.1%, according to a new report by Grand View Research, Inc. The strong product pipeline and formulation advancements are driving the market. In addition, novel innovative products are booming the market. In September 2019, Rybelsus, the first and only oral GLP-1 analog was approved by the U.S.FDA for improving the glycemic control in type-2 diabetes patients. It is a semaglutide-based product developed by Novo Nordisk, which is currently under review by European Medicines Agency (EMA) and Pharmaceuticals and Medical Devices Agency (PMDA). After receiving the approval, the market may witness significant growth over the forecast period.
Furthermore, pharmaceutical companies are focusing on research collaborations for developing new GLP-1 products. For instance, in September 2018, Eli Lilly and Company entered into a license agreement with Chugai Pharmaceutical Co., Ltd for OWL833. OWL833 is Chugai’s proprietary oral GLP-1 agonist candidate and as per the agreement Eli Lilly will obtain global commercialization and development rights.
The companies are currently aiming on geographical expansion for increasing the sales output. Novo Nordisk is expanding its business by investing in the manufacturing unit located in North Carolina. The company holds around 50.0% of the market share of GLP-1 receptor agonists and is expected to dominate the market over the forecast period. Furthermore, in July 2018, Sanofi invested about USD 74.1 million in China for establishing an R&D hub to enhance its global reach.
The companies are also focusing on getting approval for other indications like obesity and major adverse cardiovascular events by authorities like the U.S.FDA, EMEA, and others for the existing products to increase their life cycle. For instance, in January 2020, Novo Nordisk received the U.S. FDA approval for Ozempic for Major Adverse Cardiovascular Events (MACE) in type 2 diabetes patients.
GLP-1 Receptor Agonist Market Report Highlights
- Trulicity was the largest revenue-generating segment in 2019 owing to high prescription rate
- Ozempic is expected to witness the fastest growth rate over the forecast period due to the benefits like cardiovascular risk reduction, weight loss, and controlled HbA1C levels
- North America was the largest revenue-generating region in 2019, followed by Europe. The main factors contributing to their growth are increased usage of GLP-1 products, increasing R&D expenditure by government,and well-established biopharmaceutical and pharmaceutical industry in U.S. and Canada
- Asia Pacific is expected to be the fastest-growing region over the forecast period due to the increasing prevalence of diabetes that supports the uptake of the medication
- The key market players are adopting strategies such as mergers and acquisitions, product development, product extension, and regional expansion to increase their market share.
CHAPTER 1. METHODOLOGY AND SCOPE
1.1.Market Segmentation & Scope
1.2. MarketDefinition
1.3. InformationProcurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources & Third party perspectives
1.3.4. Primaryresearch
1.4. Information Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Data Visualization
1.6. Data Validation & Publishing
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
CHAPTER 3. GLP - 1 RECEPTOR AGONIST MARKET VARIABLES, TRENDS & SCOPE
3.1. Penetration & Growth Prospect Mapping
3.2. Regulatory Framework
3.2.1. Reimbursement framework
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.1.1. Formulation advancements of GLP - 1 receptor agonist
3.3.1.2. Presence of strong product pipeline
3.3.1.3. Favourable reimbursement policies
3.3.1.4. Increase in prevalence rate of lifestyle diseases
3.3.2. Market restraint analysis
3.3.2.1. Product failure
3.3.2.2. Patent expiry of blockbuster drugs during the forecast period
3.4. GLP - 1 Receptor Agonist Market Analysis Tools
3.4.1. Industry analysis - Porter’s
3.4.1.1. Supplier power (Moderate due to requirement of high - quality raw materials)
3.4.1.2. Buyer power (High due to limited number of established providers)
3.4.1.3. Substitution threat (Low due to clinical development of new compounds)
3.4.1.4. New entrants’ threat (Moderate as the market is underserved)
3.4.1.5. Competitive rivalry (Moderate due to presence of few key players)
3.4.2. PESTEL analysis
3.4.2.1. Political landscape
3.4.2.2. Environmental landscape
3.4.2.3. Social landscape
3.4.2.4. Technology landscape
3.4.2.5. Legal landscape
3.4.3. Major deals & strategic alliances analysis
3.4.3.1. Joint ventures
3.4.3.2. Mergers & acquisitions
CHAPTER 4. GLP - 1 RECEPTOR AGONIST MARKET - COMPETITIVE ANALYSIS
4.1. Recent Developments & Impact Analysis, by Key Market Participants
4.2. Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
4.3. Public Companies
4.3.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
4.3.2. Company market share
4.3.3. Synergy analysis: Major deals & strategic alliances
4.4. Private Companies
4.4.1. List of key emerging companies
4.4.2. Regional network map
4.4.3. Company market position analysis (geographic presence, product portfolio, key alliance, industry experience)
CHAPTER 5. GLP - 1 RECEPTOR AGONIST MARKET: TYPE ESTIMATES & TREND ANALYSIS
5.1. Definitions & Scope
5.2. DrugMarket Share Analysis, 2019 & 2027
5.3. GLP - 1 Receptor Agonist Market, byType, 2016 to 2027
5.4. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following,
5.4.1. Victoza
5.4.1.1 Victoza market, 2016 - 2027 (USD Million)
5.4.2. Ozempic
5.4.2.1 Ozempic market, 2016 - 2027 (USD Million)
5.4.3. Trulicity
5.4.3.1 Trulicity market, 2016 - 2027 (USD Million)
5.4.4. Bydureon
5.4.4.1 Bydureon market, 2016 - 2027 (USD Million)
5.4.5. Saxenda
5.4.5.1 Saxenda market, 2016 - 2027 (USD Million)
5.4.6. Others
5.4.6.1 Others market, 2016 - 2027 (USD Million)
CHAPTER 6 GLP - 1 RECEPTOR AGONIST MARKET: REGIONAL ESTIMATES & TREND ANALYSIS, BY TYPE
6.1 GLP - 1 Receptor Agonist Market: Regional Movement Analysis, 2018 & 2026
6.2 GLP - 1 Receptor Agonist Market: Leading Players, 2018:
6.2.1. North America
6.2.2. Europe
6.2.3. Asia Pacific
6.2.4. Latin America
6.2.5. Middle East & Africa
6.3 SWOT Analysis, by Factor (Political & Legal, Economic And Technological)
6.3.1. North America
6.3.2. Europe
6.3.3. Asia Pacific
6.3.4. Latin America
6.3.5. Middle East & Africa
6.4 North America
6.4.1 North America market, 2016 - 2027 (USD Million)
6.4.2 U.S.
6.4.2.1 U.S. market, 2016 - 2027 (USD Million)
6.4.3 Canada
6.4.3.1 Canada market, 2016 - 2027 (USD Million)
6.5. Europe
6.5.1 Europe market, 2016 - 2027 (USD Million)
6.5.2 U.K.
6.5.2.1 U.K. market, 2016 - 2027 (USD Million)
6.5.3 Germany
6.5.3.1 Germany market, 2016 - 2027 (USD Million)
6.5.4 France
6.5.4.1 France market, 2016 - 2027 (USD Million)
6.5.5 Spain
6.5.5.1 Spain market, 2016 - 2027 (USD Million)
6.5.6 Italy
6.5.6.1 Italy market, 2016 - 2027 (USD Million)
6.6 Asia Pacific
6.6.1 Asia Pacific market, 2016 - 2027 (USD Million)
6.6.2 Japan
6.6.2.1 Japan market, 2016 - 2027 (USD Million)
6.6.3 China
6.6.3.1 China market, 2016 - 2027 (USD Million)
6.6.4 Australia
6.6.4.1 Australia market, 2016 - 2027 (USD Million)
6.6.5 South Korea
6.6.5.1 South Korea market, 2016 - 2027 (USD Million)
6.7 Latin America
6.7.1 Latin America market, 2016 - 2027 (USD Million)
6.7.2 Brazil
6.7.2.1 Brazil market, 2016 - 2027 (USD Million)
6.7.3 Mexico
6.7.3.1 Mexico market, 2016 - 2027 (USD Million)
6.7.4 Argentina
6.7.4.1 Argentina market, 2016 - 2027 (USD Million)
6.8 Middle East & Africa
6.8.1 Middle East & Africa market, 2016 - 2027 (USD Million)
6.8.2 South Africa
6.8.2.1 South Africa market, 2016 - 2027 (USD Million)
6.8.3 Saudi Arabia
6.8.3.1 Saudi Arabia market, 2016 - 2027 (USD Million)
CHAPTER 7 COMPETITIVE LANDSCAPE
7.1 Strategy Framework
7.2 Heat Map Analysis of Private Companies
7.2.1 Company size
7.2.2 Distribution network
7.2.3 Product portfolio
7.2.4 Segment coverage
7.2.5 Geographic presence
7.2.6 Collaborations
7.2.7 Conclusion
7.3 Eli Lilly and Company
7.3.1 Company overview
7.3.2 Financial performance
7.3.3 Product benchmarking
7.3.4 Strategic initiatives
7.4 Sanofi
7.4.1 Company overview
7.4.2 Financial performance
7.4.3 Product benchmarking
7.4.4 Strategic initiatives
7.5 Novo Nordisk A/S
7.5.1 Company overview
7.5.2 Financial performance
7.5.3 Product benchmarking
7.5.4 Strategic initiatives
7.6 AstraZeneca
7.6.1 Company overview
7.6.2 Financial performance
7.6.3 Product benchmarking
7.6.4 Strategic initiatives
1.1.Market Segmentation & Scope
1.2. MarketDefinition
1.3. InformationProcurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources & Third party perspectives
1.3.4. Primaryresearch
1.4. Information Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Data Visualization
1.6. Data Validation & Publishing
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
CHAPTER 3. GLP - 1 RECEPTOR AGONIST MARKET VARIABLES, TRENDS & SCOPE
3.1. Penetration & Growth Prospect Mapping
3.2. Regulatory Framework
3.2.1. Reimbursement framework
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.1.1. Formulation advancements of GLP - 1 receptor agonist
3.3.1.2. Presence of strong product pipeline
3.3.1.3. Favourable reimbursement policies
3.3.1.4. Increase in prevalence rate of lifestyle diseases
3.3.2. Market restraint analysis
3.3.2.1. Product failure
3.3.2.2. Patent expiry of blockbuster drugs during the forecast period
3.4. GLP - 1 Receptor Agonist Market Analysis Tools
3.4.1. Industry analysis - Porter’s
3.4.1.1. Supplier power (Moderate due to requirement of high - quality raw materials)
3.4.1.2. Buyer power (High due to limited number of established providers)
3.4.1.3. Substitution threat (Low due to clinical development of new compounds)
3.4.1.4. New entrants’ threat (Moderate as the market is underserved)
3.4.1.5. Competitive rivalry (Moderate due to presence of few key players)
3.4.2. PESTEL analysis
3.4.2.1. Political landscape
3.4.2.2. Environmental landscape
3.4.2.3. Social landscape
3.4.2.4. Technology landscape
3.4.2.5. Legal landscape
3.4.3. Major deals & strategic alliances analysis
3.4.3.1. Joint ventures
3.4.3.2. Mergers & acquisitions
CHAPTER 4. GLP - 1 RECEPTOR AGONIST MARKET - COMPETITIVE ANALYSIS
4.1. Recent Developments & Impact Analysis, by Key Market Participants
4.2. Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
4.3. Public Companies
4.3.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
4.3.2. Company market share
4.3.3. Synergy analysis: Major deals & strategic alliances
4.4. Private Companies
4.4.1. List of key emerging companies
4.4.2. Regional network map
4.4.3. Company market position analysis (geographic presence, product portfolio, key alliance, industry experience)
CHAPTER 5. GLP - 1 RECEPTOR AGONIST MARKET: TYPE ESTIMATES & TREND ANALYSIS
5.1. Definitions & Scope
5.2. DrugMarket Share Analysis, 2019 & 2027
5.3. GLP - 1 Receptor Agonist Market, byType, 2016 to 2027
5.4. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following,
5.4.1. Victoza
5.4.1.1 Victoza market, 2016 - 2027 (USD Million)
5.4.2. Ozempic
5.4.2.1 Ozempic market, 2016 - 2027 (USD Million)
5.4.3. Trulicity
5.4.3.1 Trulicity market, 2016 - 2027 (USD Million)
5.4.4. Bydureon
5.4.4.1 Bydureon market, 2016 - 2027 (USD Million)
5.4.5. Saxenda
5.4.5.1 Saxenda market, 2016 - 2027 (USD Million)
5.4.6. Others
5.4.6.1 Others market, 2016 - 2027 (USD Million)
CHAPTER 6 GLP - 1 RECEPTOR AGONIST MARKET: REGIONAL ESTIMATES & TREND ANALYSIS, BY TYPE
6.1 GLP - 1 Receptor Agonist Market: Regional Movement Analysis, 2018 & 2026
6.2 GLP - 1 Receptor Agonist Market: Leading Players, 2018:
6.2.1. North America
6.2.2. Europe
6.2.3. Asia Pacific
6.2.4. Latin America
6.2.5. Middle East & Africa
6.3 SWOT Analysis, by Factor (Political & Legal, Economic And Technological)
6.3.1. North America
6.3.2. Europe
6.3.3. Asia Pacific
6.3.4. Latin America
6.3.5. Middle East & Africa
6.4 North America
6.4.1 North America market, 2016 - 2027 (USD Million)
6.4.2 U.S.
6.4.2.1 U.S. market, 2016 - 2027 (USD Million)
6.4.3 Canada
6.4.3.1 Canada market, 2016 - 2027 (USD Million)
6.5. Europe
6.5.1 Europe market, 2016 - 2027 (USD Million)
6.5.2 U.K.
6.5.2.1 U.K. market, 2016 - 2027 (USD Million)
6.5.3 Germany
6.5.3.1 Germany market, 2016 - 2027 (USD Million)
6.5.4 France
6.5.4.1 France market, 2016 - 2027 (USD Million)
6.5.5 Spain
6.5.5.1 Spain market, 2016 - 2027 (USD Million)
6.5.6 Italy
6.5.6.1 Italy market, 2016 - 2027 (USD Million)
6.6 Asia Pacific
6.6.1 Asia Pacific market, 2016 - 2027 (USD Million)
6.6.2 Japan
6.6.2.1 Japan market, 2016 - 2027 (USD Million)
6.6.3 China
6.6.3.1 China market, 2016 - 2027 (USD Million)
6.6.4 Australia
6.6.4.1 Australia market, 2016 - 2027 (USD Million)
6.6.5 South Korea
6.6.5.1 South Korea market, 2016 - 2027 (USD Million)
6.7 Latin America
6.7.1 Latin America market, 2016 - 2027 (USD Million)
6.7.2 Brazil
6.7.2.1 Brazil market, 2016 - 2027 (USD Million)
6.7.3 Mexico
6.7.3.1 Mexico market, 2016 - 2027 (USD Million)
6.7.4 Argentina
6.7.4.1 Argentina market, 2016 - 2027 (USD Million)
6.8 Middle East & Africa
6.8.1 Middle East & Africa market, 2016 - 2027 (USD Million)
6.8.2 South Africa
6.8.2.1 South Africa market, 2016 - 2027 (USD Million)
6.8.3 Saudi Arabia
6.8.3.1 Saudi Arabia market, 2016 - 2027 (USD Million)
CHAPTER 7 COMPETITIVE LANDSCAPE
7.1 Strategy Framework
7.2 Heat Map Analysis of Private Companies
7.2.1 Company size
7.2.2 Distribution network
7.2.3 Product portfolio
7.2.4 Segment coverage
7.2.5 Geographic presence
7.2.6 Collaborations
7.2.7 Conclusion
7.3 Eli Lilly and Company
7.3.1 Company overview
7.3.2 Financial performance
7.3.3 Product benchmarking
7.3.4 Strategic initiatives
7.4 Sanofi
7.4.1 Company overview
7.4.2 Financial performance
7.4.3 Product benchmarking
7.4.4 Strategic initiatives
7.5 Novo Nordisk A/S
7.5.1 Company overview
7.5.2 Financial performance
7.5.3 Product benchmarking
7.5.4 Strategic initiatives
7.6 AstraZeneca
7.6.1 Company overview
7.6.2 Financial performance
7.6.3 Product benchmarking
7.6.4 Strategic initiatives
LIST OF TABLES
TABLE 1 Country share estimation
TABLE 2 North America GLP - 1 receptor agonist market estimates and forecasts, by product, 2016 - 2027 (USD Million)
TABLE 3 U.S.GLP - 1 receptor agonist market estimates and forecasts, by product, 2016 - 2027 (USD Million)
TABLE 4 Canada GLP - 1 receptor agonist market estimates and forecasts, by product, 2016 - 2027 (USD Million)
TABLE 5 Europe GLP - 1 receptor agonist market estimates and forecasts, by product, 2016 - 2027 (USD Million)
TABLE 6 U.K.GLP - 1 receptor agonist market estimates and forecasts, by product, 2016 - 2027 (USD Million)
TABLE 7 Germany GLP - 1 receptor agonist market estimates and forecasts, by product, 2016 - 2027 (USD Million)
TABLE 8 France GLP - 1 receptor agonist market estimates and forecasts, by product, 2016 - 2027 (USD Million)
TABLE 9 SpainGLP - 1 receptor agonist market estimates and forecasts, by product, 2016 - 2027 (USD Million)
TABLE 10 ItalyGLP - 1 receptor agonist market estimates and forecasts, by product, 2016 - 2027 (USD Million)
TABLE 11 Asia PacificGLP - 1 receptor agonist market estimates and forecasts, by product, 2016 - 2027 (USD Million)
TABLE 12 Japan GLP - 1 receptor agonist market estimates and forecasts, by product, 2016 - 2027 (USD Million)
TABLE 13 China GLP - 1 receptor agonist market estimates and forecasts, by product, 2016 - 2027 (USD Million)
TABLE 14 AustraliaGLP - 1 receptor agonist market estimates and forecasts, by product, 2016 - 2027 (USD Million)
TABLE 15 South Korea GLP - 1 receptor agonist market estimates and forecasts, by product, 2016 - 2027 (USD Million)
TABLE 16 Latin America GLP - 1 receptor agonist market estimates and forecasts, by product, 2016 - 2027 (USD Million)
TABLE 17 BrazilGLP - 1 receptor agonist market estimates and forecasts, by product, 2016 - 2027 (USD Million)
TABLE 18 Mexico GLP - 1 receptor agonist market estimates and forecasts, by product, 2016 - 2027 (USD Million)
TABLE 19 Argentina GLP - 1 receptor agonist market estimates and forecasts, by product, 2016 - 2027 (USD Million)
TABLE 20 Middle East & AfricaGLP - 1 receptor agonist market estimates and forecasts, by product, 2016 - 2027 (USD Million)
TABLE 21 South Africa GLP - 1 receptor agonist market estimates and forecasts, by product, 2016 - 2027 (USD Million)
TABLE 22 Saudi Arabia GLP - 1 receptor agonist market estimates and forecasts, by product, 2016 - 2027 (USD Million)
TABLE 1 Country share estimation
TABLE 2 North America GLP - 1 receptor agonist market estimates and forecasts, by product, 2016 - 2027 (USD Million)
TABLE 3 U.S.GLP - 1 receptor agonist market estimates and forecasts, by product, 2016 - 2027 (USD Million)
TABLE 4 Canada GLP - 1 receptor agonist market estimates and forecasts, by product, 2016 - 2027 (USD Million)
TABLE 5 Europe GLP - 1 receptor agonist market estimates and forecasts, by product, 2016 - 2027 (USD Million)
TABLE 6 U.K.GLP - 1 receptor agonist market estimates and forecasts, by product, 2016 - 2027 (USD Million)
TABLE 7 Germany GLP - 1 receptor agonist market estimates and forecasts, by product, 2016 - 2027 (USD Million)
TABLE 8 France GLP - 1 receptor agonist market estimates and forecasts, by product, 2016 - 2027 (USD Million)
TABLE 9 SpainGLP - 1 receptor agonist market estimates and forecasts, by product, 2016 - 2027 (USD Million)
TABLE 10 ItalyGLP - 1 receptor agonist market estimates and forecasts, by product, 2016 - 2027 (USD Million)
TABLE 11 Asia PacificGLP - 1 receptor agonist market estimates and forecasts, by product, 2016 - 2027 (USD Million)
TABLE 12 Japan GLP - 1 receptor agonist market estimates and forecasts, by product, 2016 - 2027 (USD Million)
TABLE 13 China GLP - 1 receptor agonist market estimates and forecasts, by product, 2016 - 2027 (USD Million)
TABLE 14 AustraliaGLP - 1 receptor agonist market estimates and forecasts, by product, 2016 - 2027 (USD Million)
TABLE 15 South Korea GLP - 1 receptor agonist market estimates and forecasts, by product, 2016 - 2027 (USD Million)
TABLE 16 Latin America GLP - 1 receptor agonist market estimates and forecasts, by product, 2016 - 2027 (USD Million)
TABLE 17 BrazilGLP - 1 receptor agonist market estimates and forecasts, by product, 2016 - 2027 (USD Million)
TABLE 18 Mexico GLP - 1 receptor agonist market estimates and forecasts, by product, 2016 - 2027 (USD Million)
TABLE 19 Argentina GLP - 1 receptor agonist market estimates and forecasts, by product, 2016 - 2027 (USD Million)
TABLE 20 Middle East & AfricaGLP - 1 receptor agonist market estimates and forecasts, by product, 2016 - 2027 (USD Million)
TABLE 21 South Africa GLP - 1 receptor agonist market estimates and forecasts, by product, 2016 - 2027 (USD Million)
TABLE 22 Saudi Arabia GLP - 1 receptor agonist market estimates and forecasts, by product, 2016 - 2027 (USD Million)
LIST OF FIGURES
FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Market summary, 2018
FIG. 4 Market trends & outlook
FIG. 5 Market segmentation & scope
FIG. 6 Market driver relevance analysis (Current & future impact)
FIG. 7 Market restrain relevance analysis (Current & future impact)
FIG. 8 Penetration & growth prospect mapping
FIG. 9 SWOT analysis, by factor (political & legal, economic and technological)
FIG. 10 Porter’s five forces analysis
FIG. 11 GLP - 1 receptor agonist market Productoutlook key takeaways
FIG. 12 GLP - 1 receptor agonist market: Product movement analysis
FIG. 13 Global GLP - 1 receptor agonist market, 2016 - 2027 (USD Million)
FIG. 14 Regional market place: Key takeaways, 2019
FIG. 15 Regional outlook, 2019 & 2027
FIG. 16 North America GLP - 1 receptor agonist market, 2016 - 2027 (USD Million)
FIG. 17 U.S. GLP - 1 receptor agonist market, 2016 - 2027 (USD Million)
FIG. 18 Canada GLP - 1 receptor agonist market, 2016 - 2027 (USD Million)
FIG. 19 Europe GLP - 1 receptor agonist market, 2016 - 2027 (USD Million)
FIG. 20 U.K.GLP - 1 receptor agonist market, 2016 - 2027 (USD Million)
FIG. 21 Germany GLP - 1 receptor agonist market, 2016 - 2027 (USD Million)
FIG. 22 FranceGLP - 1 receptor agonist market, 2016 - 2027 (USD Million)
FIG. 23 Spain GLP - 1 receptor agonist market, 2016 - 2027 (USD Million)
FIG. 24 ItalyGLP - 1 receptor agonist market, 2016 - 2027 (USD Million)
FIG. 25 Asia Pacific GLP - 1 receptor agonist market, 2016 - 2027 (USD Million)
FIG. 26 JapanGLP - 1 receptor agonist market, 2016 - 2027 (USD Million)
FIG. 27 ChinaGLP - 1 receptor agonist market, 2016 - 2027 (USD Million)
FIG. 28 AustraliaGLP - 1 receptor agonist market, 2016 - 2027 (USD Million)
FIG. 29 South Korea GLP - 1 receptor agonist market, 2016 - 2027 (USD Million)
FIG. 30 Latin America GLP - 1 receptor agonist market, 2016 - 2027 (USD Million)
FIG. 31 BrazilGLP - 1 receptor agonist market, 2016 - 2027 (USD Million)
FIG. 32 Mexico GLP - 1 receptor agonist market, 2016 - 2027 (USD Million)
FIG. 33 Argentina GLP - 1 receptor agonist market, 2016 - 2027 (USD Million)
FIG. 34 Middle East and Africa GLP - 1 receptor agonist market, 2016 - 2027 (USD Million)
FIG. 35 South Africa GLP - 1 receptor agonist market, 2016 - 2027 (USD Million)
FIG. 36 Saudi Arabia GLP - 1 receptor agonist market, 2016 - 2027 (USD Million)
FIG. 37 Strategy framework
FIG. 38 Participant categorization
FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Market summary, 2018
FIG. 4 Market trends & outlook
FIG. 5 Market segmentation & scope
FIG. 6 Market driver relevance analysis (Current & future impact)
FIG. 7 Market restrain relevance analysis (Current & future impact)
FIG. 8 Penetration & growth prospect mapping
FIG. 9 SWOT analysis, by factor (political & legal, economic and technological)
FIG. 10 Porter’s five forces analysis
FIG. 11 GLP - 1 receptor agonist market Productoutlook key takeaways
FIG. 12 GLP - 1 receptor agonist market: Product movement analysis
FIG. 13 Global GLP - 1 receptor agonist market, 2016 - 2027 (USD Million)
FIG. 14 Regional market place: Key takeaways, 2019
FIG. 15 Regional outlook, 2019 & 2027
FIG. 16 North America GLP - 1 receptor agonist market, 2016 - 2027 (USD Million)
FIG. 17 U.S. GLP - 1 receptor agonist market, 2016 - 2027 (USD Million)
FIG. 18 Canada GLP - 1 receptor agonist market, 2016 - 2027 (USD Million)
FIG. 19 Europe GLP - 1 receptor agonist market, 2016 - 2027 (USD Million)
FIG. 20 U.K.GLP - 1 receptor agonist market, 2016 - 2027 (USD Million)
FIG. 21 Germany GLP - 1 receptor agonist market, 2016 - 2027 (USD Million)
FIG. 22 FranceGLP - 1 receptor agonist market, 2016 - 2027 (USD Million)
FIG. 23 Spain GLP - 1 receptor agonist market, 2016 - 2027 (USD Million)
FIG. 24 ItalyGLP - 1 receptor agonist market, 2016 - 2027 (USD Million)
FIG. 25 Asia Pacific GLP - 1 receptor agonist market, 2016 - 2027 (USD Million)
FIG. 26 JapanGLP - 1 receptor agonist market, 2016 - 2027 (USD Million)
FIG. 27 ChinaGLP - 1 receptor agonist market, 2016 - 2027 (USD Million)
FIG. 28 AustraliaGLP - 1 receptor agonist market, 2016 - 2027 (USD Million)
FIG. 29 South Korea GLP - 1 receptor agonist market, 2016 - 2027 (USD Million)
FIG. 30 Latin America GLP - 1 receptor agonist market, 2016 - 2027 (USD Million)
FIG. 31 BrazilGLP - 1 receptor agonist market, 2016 - 2027 (USD Million)
FIG. 32 Mexico GLP - 1 receptor agonist market, 2016 - 2027 (USD Million)
FIG. 33 Argentina GLP - 1 receptor agonist market, 2016 - 2027 (USD Million)
FIG. 34 Middle East and Africa GLP - 1 receptor agonist market, 2016 - 2027 (USD Million)
FIG. 35 South Africa GLP - 1 receptor agonist market, 2016 - 2027 (USD Million)
FIG. 36 Saudi Arabia GLP - 1 receptor agonist market, 2016 - 2027 (USD Million)
FIG. 37 Strategy framework
FIG. 38 Participant categorization
